CoChat

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

Reig, Maria, Sanduzzi-Zamparelli, Marco, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Díaz, Alba, Llarch, Neus, Iserte, Gemma, Mollà, Meritxell, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Yanagihara, Ted K., Ayuso, Carmen, Torres, Ferran, Bruix, Jordi · 2026 · Journal of Hepatology
Cited by 220

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The 2025 BCLC update incorporates recent advances in the field of treatment recommendations for hepatocellular carcinoma while preserving its simplicity. Each stage remains directly linked to its evidence-based first-option treatment. The BCLC algorithm provides guidance to evaluate patient prognosis and propose a therapeutic strategy according to the current scientific evidence. Tumor boards require structured methodologies to address clinical complexity. Beyond published evidence, decision-making should incorporate biological, psychosocial, and contextual factors that may affect morbidity, feasibility, and patient vulnerability. Such a multidimensional approach ensures treatments remain evidence-based and patient-centered. The updated clinical-decision-making chapter embeds the CUSE framework (Complexity, Uncertainty, Subjectivity, Emotion). CUSE turns unavoidable doubt into a shared, iterative process to: (i) define the therapeutic goal (survival, tumor control, quality of life, etc.); (ii) grade each option, noting evidence strength and gaps; (iii) align choices with comorbidities, feasibility, oncologic risk, and patient values and goals; and (iv) select a plan with regular check-ins as new information or needs arise. IMPACT AND IMPLICATIONS: The 2025 BCLC update provides the scientific justification for integrating recent advances into a cohesive, evidence-based framework that remains the global reference for prognostication and treatment allocation in HCC. By incorporating the CUSE framework, it provides multidisciplinary teams with a structured approach to navigate evidence gaps, explicitly address uncertainty, and tailor therapy to patient goals and context. These updates are particularly important for clinicians, tumor boards, and guideline developers, as well as for patients and caregivers who face complex choices in real-world practice. In practical terms, the prognostic capacity of BCLC is embedded within person-centered decision-making, fostering iterative treatment planning and laying the foundation for future studies assessing the clinical impact of CUSE, while acknowledging the need for validation and variability in implementation across healthcare settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2025.10.020

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 220

Metadata

Authors
Reig, M., Sanduzzi-Zamparelli, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Díaz, A., Llarch, N., Iserte, G., Mollà, M., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Yanagihara, T. K., Ayuso, C., Torres, F., & Bruix, J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2026-03
Volume
84
Issue
3
Pages
631-654
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4415559753
Cited by
220
References
24
FWCI
107.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.